Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation

Reuters2025-09-03

<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation

Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564339566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564339566","market":"nz","top_or_hot":-1,"title":"Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-03 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL4TYCX0:1","article_id":"2564339566","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564339566","pubTimestamp":1756903217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha  treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CNTB":"康乃德生物医药"},"translate_title":"Connect Biopharma在最新演示中展示了Rademikibart在哮喘和COPD治疗方面的巨大潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":0.9},"content_text":"Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    \n\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564339566","isCrawlerRequest":true}